Danaher Corporation

What does Danaher Corporation own?
Danaher owns approximately 15 operating companies across three segments. In Biotechnology, it owns Cytiva and Pall Corporation. In Life Sciences, it owns Leica Microsystems, Molecular Devices, Integrated DNA Technologies, SCIEX, and Beckman Coulter Life Sciences. In Diagnostics, it owns Beckman Coulter Diagnostics, Cepheid, Radiometer, Leica Biosystems, and Masimo. It also owns environmental and applied solutions brands including Hach and Videojet.

Is Danaher Corporation publicly traded?
Yes. Danaher Corporation is publicly traded on the New York Stock Exchange under the ticker symbol DHR. The company is a component of the S&P 500 and is owned by institutional investors, mutual funds, and individual shareholders. There is no parent company or controlling shareholder.

Who founded Danaher Corporation?
Danaher was founded in 1969 by brothers Steven M. Rales and Mitchell P. Rales in Washington, D.C. The Rales brothers established the company as a diversified industrial conglomerate and built it into a global life sciences and diagnostics leader through decades of disciplined acquisitions and operational improvement.

Where is Danaher Corporation headquartered?
Danaher is headquartered in Washington, D.C., USA. The company's corporate offices are based in the Washington, D.C. metropolitan area, with operating companies and manufacturing facilities distributed across the United States, Europe, Asia, and the Americas.

How many brands does Danaher Corporation own?
Danaher owns approximately 15 operating companies across its three segments. These include well-known brands in life sciences and diagnostics such as Cytiva, Pall, Leica Microsystems, Beckman Coulter, Cepheid, Radiometer, and Masimo. The company also owns environmental and industrial brands including Hach and Videojet.

Who owns Danaher Corporation?
Danaher is an independent publicly traded corporation with no parent company. The company is owned by institutional investors, mutual funds, and individual shareholders who hold its NYSE-listed common stock. The Rales brothers remain significant shareholders and board members but do not hold a controlling stake. Major institutional holders include Vanguard Group, BlackRock, and State Street Corporation.

What were Danaher's recent financial results?
For FY2025, Danaher reported $24.6 billion in revenue and $3.6 billion in net earnings. In Q2 2026, revenue was $6.3 billion, up 5.5%, with net earnings of $870 million and adjusted EPS of $1.94, up 8.0%. The company raised its 2026 guidance to adjusted EPS of $8.45 to $8.60 and core revenue growth of 3.0% to 4.0%.

Has Danaher made major acquisitions recently?
In June 2026, Danaher completed the acquisition of Masimo Corporation for $9.9 billion, adding pulse oximetry and patient monitoring to its Diagnostics segment. In 2023, Danaher acquired Abcam for approximately $5.7 billion. The largest acquisition in company history was Cytiva (formerly GE Life Sciences) for $21.4 billion in 2016.

Danaher Corporation was founded in 1969 by brothers Steven M. Rales and Mitchell P. Rales in Washington, D.C. The company began as a diversified industrial conglomerate, acquiring manufacturing businesses across multiple sectors. The Rales brothers established the company with a disciplined, acquisition-driven model focused on operational improvement through what would become the Danaher Business System.

Throughout the 1970s and 1980s, Danaher expanded through acquisitions in industrial and manufacturing markets. The company built a reputation for buying underperforming businesses and applying DBS principles to improve their operations, margins, and market positions. This approach generated consistent returns and allowed Danaher to compound revenue and earnings over decades.

In the 1990s and 2000s, Danaher began shifting its portfolio toward higher-growth, higher-margin businesses in life sciences, diagnostics, and environmental solutions. This strategic repositioning was driven by the recognition that healthcare and life sciences markets offered better long-term growth prospects than traditional industrial manufacturing.

Key acquisitions during this transformation included Beckman Coulter in 2011 for $6.8 billion, which added clinical diagnostics to the portfolio, and Cepheid in 2016 for $4.3 billion, which added molecular diagnostics and point-of-care testing. Also in 2011, Danaher acquired Pall Corporation for $3.8 billion, adding filtration and separation technology for biopharmaceutical manufacturing.

In 2016, Danaher acquired Cytiva (then part of GE Life Sciences) in a $21.4 billion deal, which was the largest acquisition in company history. This deal significantly expanded Danaher's biotechnology segment, adding bioprocessing tools and consumables used in the manufacture of biologics and vaccines.

In 2018, Danaher spun off its industrial segment as Fortive Corporation, a separate publicly traded company. This spin-off allowed Danaher to focus entirely on life sciences, diagnostics, and environmental solutions, completing its transformation from a diversified industrial conglomerate to a specialized healthcare technology company.

In 2023, Danaher acquired Abcam, a protein consumables maker, for approximately $5.7 billion. This was Danaher's largest deal since the Cytiva acquisition and expanded the company's life sciences reagent portfolio.

For FY2025, Danaher reported $24.6 billion in revenue and $3.6 billion in net earnings. The Biotechnology segment was the standout performer, with Q4 2025 revenue increasing 9.0% to $2.03 billion, driven by robust bioprocessing demand.

In February 2026, Danaher announced a definitive agreement to acquire Masimo Corporation for $180 per share in cash, a total enterprise value of approximately $9.9 billion. Masimo is a specialty diagnostics provider of pulse oximetry and patient monitoring solutions, primarily in acute care settings. The acquisition was completed on June 10, 2026, and Masimo became a wholly-owned subsidiary operating within Danaher's Diagnostics segment alongside Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter Diagnostics. Danaher expects Masimo to generate EBITDA of more than $530 million in 2027, with more than $125 million in annual cost synergies and more than $50 million in annual revenue synergies by the fifth full year.

In Q1 2026, Danaher reported revenue of $6.0 billion, up 3.5%, with adjusted EPS of $2.06, up 9.5%. In Q2 2026, revenue was $6.3 billion, up 5.5%, with net earnings of $870 million and adjusted EPS of $1.94, up 8.0%. The company raised its full-year 2026 guidance to adjusted EPS of $8.45 to $8.60 and narrowed core revenue growth expectations to 3.0% to 4.0%.

Danaher has established science-based targets for carbon emissions reduction and publishes an annual sustainability report. The company's sustainability strategy focuses on reducing the environmental footprint of its manufacturing operations, improving energy efficiency, and developing products that support sustainable healthcare and scientific research.

The company has committed to reducing Scope 1 and Scope 2 greenhouse gas emissions and has set science-based targets that are independently verified. Danaher has increased renewable energy use across its facilities and has implemented waste reduction programs in its manufacturing operations.

On ethical grounds, Danaher maintains compliance programs for medical device regulation, clinical laboratory standards, and research ethics. The company's diagnostics products are subject to FDA regulation and international medical device standards, requiring rigorous quality control and post-market surveillance. Danaher also maintains policies on responsible research practices, data integrity, and conflict of interest management.

Danaher is not a Certified B Corporation. The company's sustainability flags include science-based targets, which are independently verified.

Danaher has received recognition from independent organizations for its corporate performance:

• Fortune Most Admired Companies (2024, 2025): Named one of the world's most admired companies in the healthcare and life sciences sector
• Forbes Global 2000: Ranked among the world's largest public companies
• Newsweek America's Most Responsible Companies: Recognized for corporate responsibility and sustainability practices
• Great Place to Work: Certifications at multiple Danaher operating companies globally

These recognitions are based on independent assessments by the respective organizations.

Danaher operates in a highly regulated industry and faces ongoing regulatory oversight across its business.

Medical device regulation: Danaher's diagnostics products, including those from Beckman Coulter, Cepheid, and Masimo, are subject to FDA regulation and international medical device standards. The company must maintain regulatory clearances and approvals for its products and is subject to facility inspections, quality system audits, and post-market surveillance requirements. Any regulatory action or product recall could affect revenue and reputation.

Masimo acquisition antitrust review: The $9.9 billion acquisition of Masimo, completed in June 2026, was subject to regulatory review including antitrust clearance. The deal was approved after review by relevant regulatory bodies, though the combination of Masimo's pulse oximetry business with Danaher's existing diagnostics portfolio drew scrutiny regarding market concentration in acute care monitoring.

Pricing and reimbursement pressure: Danaher's diagnostics businesses face pressure from healthcare payers and government health systems seeking to control diagnostic testing costs. In the United States, the Protecting Access to Medicare Act (PAMA) has reduced reimbursement rates for clinical laboratory tests, affecting revenue growth in the diagnostics segment.

Respiratory testing revenue decline: Cepheid's respiratory testing revenue, which surged during the COVID-19 pandemic, has been declining as testing volumes return to pre-pandemic levels. This decline has been a headwind for the Diagnostics segment, though core growth excluding respiratory testing has been stronger.

Geopolitical risks: Danaher operates globally, with significant revenue from China, Europe, and other international markets. U.S.-China trade tensions, export controls on biotechnology, and currency fluctuations have affected reported revenue growth. In Q2 2026, currency exchange rates reduced total sales growth by 1.0 percentage points.